ArticleMolecular biology reports2025
Chlorogenic acid-rich Morus alba leaf alleviated renal fibrosis through the regulation of transforming growth factor-beta 1 (TGF-β1) and fibroblast growth factor-2 (FGF-2), and extracellular matrix deposition.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) progression is linked to renal fibrosis, influenced by profibrotic factors like transforming growth factor-beta 1 (TGF-β1) and fibroblast growth factor-2 (FGF-2). Despite advancements in synthetic drugs like enalapril, evidence for plant-derived candidates that slow kidney fibrosis remains limited, underscoring the need for rigorous preclinical evaluation.
objectiveThis study evaluates the antifibrotic efficacy of Morus alba Linn. leaf extract (MLE) and its primary compound, chlorogenic acid (CGA), in a mouse model of renal fibrosis induced by unilateral ureteral obstruction (UUO). MATERIALS AND
methodsTwenty-five male Balb/c mice were assigned to five groups: sham operation (SO), UUO control, UUO with enalapril treatment, UUO with MLE, and UUO with CGA. Treatments were administered orally for 14 days, followed by assessments of fibrosis through histological analysis, immunohistochemistry, gene expression profiling, and molecular docking.
resultsResults indicated significant reductions in basement membrane thickening (from 31.19% in UUO to 21.87% with MLE), collagen deposition (from 6.85% to 2.7%), and decreased expression of key fibrotic markers such as TGF-β1 (from 26.21% to 11.91% with MLE and 5.92% with CGA), FGF-2, Collagen-1, Smad3, alpha-smooth muscle actin (α-SMA), and β-catenin. Molecular docking analysis suggested that CGA formed plausible interactions with transforming growth factor beta receptor 1 (TGFβR1) (-9.5 kcal/mol) and fibroblast growth factor receptor 2 (FGFR2) (-8.3 kcal/mol), indicating its potential antifibrotic properties.
conclusionThese findings suggest that MLE and CGA effectively alleviate renal fibrosis by modulating crucial profibrotic signaling pathways, presenting them as promising natural therapeutic alternatives for CKD-associated fibrosis.
Indexed as
Identifiers
41343096What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.